பில் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from பில் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In பில் இன்க் Today - Breaking & Trending Today
Palo Alto auto sales tech startup Roadster scooped up for $360M - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Lupin, Phil Inc partner to deliver solutions for patients on Solosec® Lupin, Phil Inc partner to deliver solutions for patients on Solosec® 02 February 2021 | News Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women Source credit: Lupin Lupin Pharmaceuticals, Inc, a global pharmaceutical company, has announced a partnership with Phil, Inc, which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women. This treatment is designed to deliver a full course of therapy in just one packet. ....
Share this article Share this article MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ Lupin Pharmaceuticals Inc. (Lupin), global pharmaceutical company, announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet. 1 In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021. ....